Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.
For media inquiries, contact
Vice President for Communications
Ludwig scientists shared data on clinical and other studies at 2017 International Cancer Immunotherapy Conference
SEPTEMBER 11, 2017, NEW YORK – Ludwig Cancer Research scientists presented a range of data on cancer immunology and immunotherapy in poster sessions and oral presentations at the International Cancer Immunotherapy Conference in Mainz/Frankfurt, Germany, September 6-9, 2017. The full program can be viewed here.
Ludwig is currently sponsoring and managing several trials that evaluate different immunotherapy treatments in combination with each other and with chemotherapy or radiotherapy to treat a variety of cancers, including melanoma, esophageal cancer and non-small cell lung cancer.
Two of the trials presented at the conference are jointly managed by Ludwig and the Cancer Research Institute. These are:
- A Phase 1/2 study to evaluate safety and efficacy of an ALK inhibitor, ensartinib, and a PD-L1 antibody, durvalumab, in patients with ALK-rearranged non-small cell lung cancer (NSCLC)
- A Phase 1/2 study of in situ vaccination with tremelimumab + intravenous durvalumab + poly‑ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors
Other studies presented are independently sponsored by Ludwig’s Clinical Trials Management Team. These include:
- Phase 1 study to evaluate safety and efficacy of ipilimumab + nivolumab + external beam radiotherapy in patients with metastatic melanoma
- Phase 1/2 study to evaluate durvalumab ± tremelimumab + chemo(radio)therapy in patients with esophageal cancer
Ludwig scientists also presented results of studies mapping the tumor immune microenvironment, developing new approaches to the personalization of immunotherapy, exploring the various roles of T regulatory cells in cancer progression and unraveling the causes of resistance to cancer immunotherapy.
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For further information please contact Rachel Steinhardt, email@example.com or +1-212-450-1582.